Shares of pharmaceutical company Open Orphan (LON: ORPH) are up over 3% on Friday after the company said its subsidiary, hVIVO, has launched its Disease in Motion platform.
The data-focused platform includes clinical, immunological, virological and digital (wearable) biomarkers and has multiple infectious disease applications that apply to a wide variety of end-users, including big tech, wearables, pharma and biotech companies.
hVIVO, which has built up a comprehensive, multi-parametric bio and databank, said the Disease in Motion platform dataset is continuously gathered throughout the onset, progression, and resolution of an infection, which is enabled by hVIVO's challenge study model.
“As a recognised global leader in supporting the development of therapeutics and vaccines, hVIVO and our team of virological, clinical and regulatory experts are actively in discussion with potential partners to help address the next set of challenges facing humanity,” said Cathal Friel, Executive Chairman of Open Orphan.
Open Orphan’s share price is currently trading at 41.50p, up 3.50% following the news. In 2021, it has gained over 60% after a strong 2020 performance that saw it start at 4.70p and end the year at 25.80p.
Should you invest in Open Orphan shares?
Open Orphan shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Open Orphan shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
